TABLE 7.

The relationships between the deep gray nuclear DTI metrics and clinical measures described by Partial Pearson correlation analysis, controlling for age, gender, and levodopa equivalent dose (full and subset cohorts).

Clinical score	Disease duration			H&Y			UPDRS III
Deep gray nuclei	Coefficient r	p-value	Corrected p-value	Coefficient r	p-value	Corrected p-value	Coefficient r	p-value	Corrected p-value
Full cohort
FA (ratio)
Caudate	−0.1256	0.1559	N.S.	−0.1085	0.2209	N.S.	−0.1866	0.0342	N.S.
Putamen	0.1528	0.0838	N.S.	0.0875	0.3241	N.S.	0.0619	0.486	N.S.
Globus Pallidus	−0.2579	0.0032	N.S.	−0.0325	0.7143	N.S.	−0.0505	0.5696	N.S.
Thalamus	0.2223	0.0113	N.S.	0.0662	0.4555	N.S.	0.0301	0.7343	N.S.
MD (10– 3 mm2/s)
Caudate	0.3942	4.0 × 10– 6	9.6 × 10– 5	0.2764	0.0015	0.03	0.3053	4.7 × 10– 4	0.0108
Putamen	0.2857	0.001	0.021	0.2111	0.0163	N.S.	0.1422	0.1078	N.S.
Globus pallidus	0.3104	0.0003	0.0066	0.0617	0.4871	N.S.	0.07	0.4308	N.S.
Thalamus	0.1801	0.0412	N.S.	0.0914	0.3031	N.S.	0.1454	0.1002	N.S.
Subset cohort
FA (ratio)
Caudate	−0.1616	0.3065	N.S.	−0.1807	0.252	N.S.	−0.3642	0.0177	N.S.
Putamen	0.1109	0.4845	N.S.	−0.042	0.7918	N.S.	0.0197	0.9016	N.S.
Globus pallidus	−0.2524	0.1067	N.S.	−0.0795	0.6166	N.S.	−0.0387	0.808	N.S.
Thalamus	0.0814	0.6083	N.S.	0.012	0.9399	N.S.	−0.0168	0.9161	N.S.
MD (10– 3 mm2/s)
Caudate	0.6377	6 × 10– 6	1.4 × 10– 4	0.3479	0.024	N.S.	0.4166	0.0061	N.S.
Putamen	0.5196	0.0004	0.0092	0.357	0.0203	N.S.	0.1504	0.3417	N.S.
Globus pallidus	0.425	0.005	N.S.	0.164	0.2992	N.S.	0.0106	0.9471	N.S.
Thalamus	0.3967	0.0092	N.S.	0.1956	0.2146	N.S.	0.3077	0.4746	N.S.

Statistical significance is defined at corrected-p < 0.05 (marked in bold).

FA, fractional anisotropy; H&Y, Hoehn and Yahr staging; MD, mean diffusivity; N.S., not significant; PD, Parkinson’s disease; UPDRS, Unified Parkinson Disease Rating Scale.